Condition: Cardiovascular Diseases · Dyslipidemias · Inflammation · Sponsor: Universidade Federal Fluminense
The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.
This description comes directly from the study's public registry record.
Denise Mafra, PhD · +5521985683003 · dmafra30@gmail.com
Ludmila Cardozo, PhD · +5521987333185 · ludmila.cardozo@gmail.com
Always discuss trial participation with your own doctor first.
| Denise Mafra | Rio de Janeiro, Rio de Janeiro, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06183307